NASDAQ · SPRY
ARS Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SPRY: Nov 05, 2026
ARS Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.34. The reported EPS for the same quarter last year was $-0.52.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.34 | $-0.27 | $-0.40 | 2 |
| Dec 2026 | $-0.35 | $-0.28 | $-0.42 | 2 |
| Mar 2027 | $-0.35 | $-0.29 | $-0.41 | 2 |
| Jun 2027 | $-0.21 | $-0.16 | $-0.26 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · RTTNews · MarketBeat- Zacks · Oct 29, 9:00 AM EDTARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseARS Pharmaceuticals, Inc. (SPRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- The Motley Fool · Aug 20, 5:01 PM EDTARS Pharma (SPRY) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 20, 9:55 AM EDTCan ARS Pharmaceuticals, Inc. (SPRY) Climb 297.02% to Reach the Level Wall Street Analysts Expect?The average of price targets set by Wall Street analysts indicates a potential upside of 297% in ARS Pharmaceuticals, Inc. (SPRY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock
- RTTNews · Aug 18, 8:33 AM EDTARS Pharma Refocuses Strategy As Q2 Revenue Hits $33.7M(RTTNews) – ARS Pharmaceuticals, Inc. (SPRY), a biopharmaceutical company focused on developing and commercializing needle-free treatments for allergic reactions and anaphylaxis, recently reported second-quarter 2026 financial results and outlined strategic priorities aimed at dr
- MarketBeat · Aug 13, 11:04 PM EDTARS Pharmaceuticals Q2 Earnings Call HighlightsARS Pharmaceuticals (NASDAQ:SPRY) outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused promotion for its neffy intranasal epinephrine product, lower operating expenses
- Zacks · Aug 13, 5:35 PM EDTARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue EstimatesARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -14.55% and +5.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 9:50 AM EDTCronos Group (CRON) Surpasses Q2 Earnings and Revenue EstimatesCronos (CRON) delivered earnings and revenue surprises of +200.00% and +24.11%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jul 8, 3:07 AM EDTARS Appoints Casale As CEO Following Sudden Departure Of Lowenthal(RTTNews) – ARS Pharmaceuticals Inc. (SPRY), a biopharmaceutical company, on Tuesday announced the immediate succession of Chief Executive Officer (CEO) from co-founder Richard Lowenthal to current President Donn Casale.
- Zacks · Jul 8, 2:52 AM EDTStrength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- The Motley Fool · May 18, 9:27 AM EDTARS Pharma (SPRY) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · May 15, 5:58 PM EDTARS Pharma (SPRY) Q4 2025 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 15, 12:09 PM EDTARS Pharmaceuticals Q1 Earnings Call HighlightsARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy, its needle-free epinephrine treatment for allergic reactions including anap
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for ARS Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.